卵巣がん治療薬市場：治療薬クラス別、モダリティ別、薬剤別-2025-2030年の世界予測

卵巣がん治療薬市場は、2023年に39億5,000万米ドルと評価され、2024年には44億9,000万米ドルに達すると予測され、CAGR 13.75%で成長し、2030年には97億3,000万米ドルに達すると予測されています。

卵巣がん治療薬市場の範囲には、卵巣がんを標的とした薬理学的治療の開発、生産、流通が含まれます。これには、化学療法剤、標的療法、免疫療法が含まれます。卵巣がん治療薬の必要性は、卵巣がんに関連する死亡率の高さによって強調されており、その主な原因はしばしば末期診断であるため、生存率と患者の転帰を改善するために効果的な薬物療法が不可欠です。治療主な用途は、主に腫瘍医や医療施設による治療体制で、最終用途は病院、がん専門治療センター、クリニックに及ぶ。

市場の成長は、個別化医療の進歩、研究開発投資の増加、疾患に対する世界の認知度の拡大といった要因に大きく影響されます。標的療法や併用療法を含む革新的な治療法の台頭は、新薬の規制当局による承認の増加と同様に、大きな成長の可能性をもたらします。低侵襲治療の選択肢や治療成績の改善に対する需要の高まりも、市場拡大の新たな機会を生み出しています。こうした機会を活用するための推奨事項としては、精密腫瘍学への投資や戦略的提携による患者アクセスの強化などが挙げられます。

しかし、市場は高い薬剤開発コスト、厳しい規制要件、既存療法に伴う潜在的な副作用などの制約に直面しています。さらに、卵巣がんは遺伝的に多様であるため、万能の治療法を開発することは困難であり、しばしば複雑な治療戦略が必要となります。

技術革新が必要な分野としては、早期発見のためのバイオマーカーの開発、新規ドラッグデリバリー・システムの開発、人工知能やゲノムの知見を活用した患者特異的治療法などが挙げられます。さらに、この市場の性質は、製薬会社、バイオテクノロジー企業、研究機関がパートナーシップを結び、競争的でありながら協調的です。画期的な治療法や適応性の高い臨床試験デザインに注力する企業は、この進化する市場情勢をリードする立場にあります。このようなダイナミクスを踏まえると、利害関係者は長期的なイノベーションと成長を促進するために、患者中心のデザインとデジタルに統合されたヘルスケアソリューションを優先すべきです。

市場力学：急速に進化する卵巣がん治療薬市場における主要市場インサイトの解明

卵巣がん治療薬市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的決定の精緻化、そして新たなビジネスチャンスの獲得に備えることができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができるとともに、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 世界の卵巣がん罹患率の上昇
  • 世界の女性の老年人口の増加
  • 新薬の採用と強力な開発パイプライン
• 市場抑制要因
  • 抗がん剤の人体への悪影響
• 市場機会
  • 新興諸国における政府によるヘルスケア産業への資金提供の増加
  • 新興経済諸国における卵巣がん治療薬の発展
• 市場の課題
  • 卵巣がんの治療費は高額

ポーターの5つの力：卵巣がん治療薬市場をナビゲートする戦略ツール

ポーターの5つの力フレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：卵巣がん治療薬市場における外部からの影響の把握

外部マクロ環境要因は、卵巣がん治療薬市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析卵巣がん治療薬市場における競合情勢の把握

卵巣がん治療薬市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックス卵巣がん治療薬市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、卵巣がん治療薬市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によってベンダーを明確かつ正確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨卵巣がん治療薬市場における成功への道筋を描く

卵巣がん治療薬市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を見直すことで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネスチャンスを活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目分野を網羅した市場の包括的な分析を提供しています：

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力の評価。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 世界中で卵巣がんの発生率が上昇
    • 世界中で高齢女性人口が増加
    • 新薬の導入と強力な開発パイプライン
  • 抑制要因
    • 抗がん剤が人体に及ぼす悪影響
  • 機会
    • 新興諸国における政府によるヘルスケア産業への資金提供の増加
    • 新興経済における卵巣がん治療薬の動向
  • 課題
    • 卵巣がんの治療にかかる費用は高額である
• 市場セグメンテーション分析
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境

第6章 卵巣がん治療薬市場治療クラス別

• 血管新生阻害剤
• PARP阻害剤
• PD-L1阻害剤

第7章 卵巣がん治療薬市場：モダリティ別

• 化学療法
• ホルモン療法
• 標的療法

第8章 卵巣がん治療薬市場薬物別

• アバスチン
• カルボプラチン
• ドキシル
• リンパルザ
• ヨンデリス

第9章 南北アメリカの卵巣がん治療薬市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第10章 アジア太平洋地域の卵巣がん治療薬市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第11章 欧州・中東・アフリカの卵巣がん治療薬市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第12章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
• 戦略分析と提言

企業一覧

• Abbott Laboratories
• Alkem Laboratories Ltd.
• Allergan PLC
• AstraZeneca PLC
• Boehringer Ingelheim
• Cipla Ltd.
• Clovis Oncology
• F. Hoffmann-La Roche AG
• Fresenius Kabi India Pvt. Ltd.
• GlaxoSmithKline PLC
• Merck & Co., Inc.
• Mylan Pharmaceuticals Pvt. Ltd.
• Pfizer, Inc.
• Sanofi S.A.
• Syndax Pharmaceuticals, Inc.

LIST OF FIGURES

• FIGURE 1. OVARIAN CANCER DRUGS MARKET RESEARCH PROCESS
• FIGURE 2. OVARIAN CANCER DRUGS MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL OVARIAN CANCER DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL OVARIAN CANCER DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL OVARIAN CANCER DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL OVARIAN CANCER DRUGS MARKET SIZE, BY THERAPEUTICS CLASS, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL OVARIAN CANCER DRUGS MARKET SIZE, BY THERAPEUTICS CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL OVARIAN CANCER DRUGS MARKET SIZE, BY MODALITY, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL OVARIAN CANCER DRUGS MARKET SIZE, BY MODALITY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL OVARIAN CANCER DRUGS MARKET SIZE, BY DRUGS, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL OVARIAN CANCER DRUGS MARKET SIZE, BY DRUGS, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. AMERICAS OVARIAN CANCER DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 13. AMERICAS OVARIAN CANCER DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. UNITED STATES OVARIAN CANCER DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 15. UNITED STATES OVARIAN CANCER DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. ASIA-PACIFIC OVARIAN CANCER DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 17. ASIA-PACIFIC OVARIAN CANCER DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. EUROPE, MIDDLE EAST & AFRICA OVARIAN CANCER DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 19. EUROPE, MIDDLE EAST & AFRICA OVARIAN CANCER DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. OVARIAN CANCER DRUGS MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 21. OVARIAN CANCER DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. OVARIAN CANCER DRUGS MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL OVARIAN CANCER DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL OVARIAN CANCER DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL OVARIAN CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. OVARIAN CANCER DRUGS MARKET DYNAMICS
• TABLE 7. GLOBAL OVARIAN CANCER DRUGS MARKET SIZE, BY THERAPEUTICS CLASS, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL OVARIAN CANCER DRUGS MARKET SIZE, BY ANGIOGENESIS INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL OVARIAN CANCER DRUGS MARKET SIZE, BY PARP INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL OVARIAN CANCER DRUGS MARKET SIZE, BY PD-L1 INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL OVARIAN CANCER DRUGS MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL OVARIAN CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL OVARIAN CANCER DRUGS MARKET SIZE, BY HORMONAL THERAPY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL OVARIAN CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL OVARIAN CANCER DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL OVARIAN CANCER DRUGS MARKET SIZE, BY AVASTIN, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL OVARIAN CANCER DRUGS MARKET SIZE, BY CARBOPLATIN, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL OVARIAN CANCER DRUGS MARKET SIZE, BY DOXIL, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL OVARIAN CANCER DRUGS MARKET SIZE, BY LYNPARZA, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL OVARIAN CANCER DRUGS MARKET SIZE, BY YONDELIS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 21. AMERICAS OVARIAN CANCER DRUGS MARKET SIZE, BY THERAPEUTICS CLASS, 2018-2030 (USD MILLION)
• TABLE 22. AMERICAS OVARIAN CANCER DRUGS MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
• TABLE 23. AMERICAS OVARIAN CANCER DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 24. AMERICAS OVARIAN CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 25. ARGENTINA OVARIAN CANCER DRUGS MARKET SIZE, BY THERAPEUTICS CLASS, 2018-2030 (USD MILLION)
• TABLE 26. ARGENTINA OVARIAN CANCER DRUGS MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
• TABLE 27. ARGENTINA OVARIAN CANCER DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 28. BRAZIL OVARIAN CANCER DRUGS MARKET SIZE, BY THERAPEUTICS CLASS, 2018-2030 (USD MILLION)
• TABLE 29. BRAZIL OVARIAN CANCER DRUGS MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
• TABLE 30. BRAZIL OVARIAN CANCER DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 31. CANADA OVARIAN CANCER DRUGS MARKET SIZE, BY THERAPEUTICS CLASS, 2018-2030 (USD MILLION)
• TABLE 32. CANADA OVARIAN CANCER DRUGS MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
• TABLE 33. CANADA OVARIAN CANCER DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 34. MEXICO OVARIAN CANCER DRUGS MARKET SIZE, BY THERAPEUTICS CLASS, 2018-2030 (USD MILLION)
• TABLE 35. MEXICO OVARIAN CANCER DRUGS MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
• TABLE 36. MEXICO OVARIAN CANCER DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 37. UNITED STATES OVARIAN CANCER DRUGS MARKET SIZE, BY THERAPEUTICS CLASS, 2018-2030 (USD MILLION)
• TABLE 38. UNITED STATES OVARIAN CANCER DRUGS MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
• TABLE 39. UNITED STATES OVARIAN CANCER DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 40. UNITED STATES OVARIAN CANCER DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 41. ASIA-PACIFIC OVARIAN CANCER DRUGS MARKET SIZE, BY THERAPEUTICS CLASS, 2018-2030 (USD MILLION)
• TABLE 42. ASIA-PACIFIC OVARIAN CANCER DRUGS MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
• TABLE 43. ASIA-PACIFIC OVARIAN CANCER DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 44. ASIA-PACIFIC OVARIAN CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 45. AUSTRALIA OVARIAN CANCER DRUGS MARKET SIZE, BY THERAPEUTICS CLASS, 2018-2030 (USD MILLION)
• TABLE 46. AUSTRALIA OVARIAN CANCER DRUGS MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
• TABLE 47. AUSTRALIA OVARIAN CANCER DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 48. CHINA OVARIAN CANCER DRUGS MARKET SIZE, BY THERAPEUTICS CLASS, 2018-2030 (USD MILLION)
• TABLE 49. CHINA OVARIAN CANCER DRUGS MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
• TABLE 50. CHINA OVARIAN CANCER DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 51. INDIA OVARIAN CANCER DRUGS MARKET SIZE, BY THERAPEUTICS CLASS, 2018-2030 (USD MILLION)
• TABLE 52. INDIA OVARIAN CANCER DRUGS MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
• TABLE 53. INDIA OVARIAN CANCER DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 54. INDONESIA OVARIAN CANCER DRUGS MARKET SIZE, BY THERAPEUTICS CLASS, 2018-2030 (USD MILLION)
• TABLE 55. INDONESIA OVARIAN CANCER DRUGS MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
• TABLE 56. INDONESIA OVARIAN CANCER DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 57. JAPAN OVARIAN CANCER DRUGS MARKET SIZE, BY THERAPEUTICS CLASS, 2018-2030 (USD MILLION)
• TABLE 58. JAPAN OVARIAN CANCER DRUGS MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
• TABLE 59. JAPAN OVARIAN CANCER DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 60. MALAYSIA OVARIAN CANCER DRUGS MARKET SIZE, BY THERAPEUTICS CLASS, 2018-2030 (USD MILLION)
• TABLE 61. MALAYSIA OVARIAN CANCER DRUGS MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
• TABLE 62. MALAYSIA OVARIAN CANCER DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 63. PHILIPPINES OVARIAN CANCER DRUGS MARKET SIZE, BY THERAPEUTICS CLASS, 2018-2030 (USD MILLION)
• TABLE 64. PHILIPPINES OVARIAN CANCER DRUGS MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
• TABLE 65. PHILIPPINES OVARIAN CANCER DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 66. SINGAPORE OVARIAN CANCER DRUGS MARKET SIZE, BY THERAPEUTICS CLASS, 2018-2030 (USD MILLION)
• TABLE 67. SINGAPORE OVARIAN CANCER DRUGS MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
• TABLE 68. SINGAPORE OVARIAN CANCER DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 69. SOUTH KOREA OVARIAN CANCER DRUGS MARKET SIZE, BY THERAPEUTICS CLASS, 2018-2030 (USD MILLION)
• TABLE 70. SOUTH KOREA OVARIAN CANCER DRUGS MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
• TABLE 71. SOUTH KOREA OVARIAN CANCER DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 72. TAIWAN OVARIAN CANCER DRUGS MARKET SIZE, BY THERAPEUTICS CLASS, 2018-2030 (USD MILLION)
• TABLE 73. TAIWAN OVARIAN CANCER DRUGS MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
• TABLE 74. TAIWAN OVARIAN CANCER DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 75. THAILAND OVARIAN CANCER DRUGS MARKET SIZE, BY THERAPEUTICS CLASS, 2018-2030 (USD MILLION)
• TABLE 76. THAILAND OVARIAN CANCER DRUGS MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
• TABLE 77. THAILAND OVARIAN CANCER DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 78. VIETNAM OVARIAN CANCER DRUGS MARKET SIZE, BY THERAPEUTICS CLASS, 2018-2030 (USD MILLION)
• TABLE 79. VIETNAM OVARIAN CANCER DRUGS MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
• TABLE 80. VIETNAM OVARIAN CANCER DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 81. EUROPE, MIDDLE EAST & AFRICA OVARIAN CANCER DRUGS MARKET SIZE, BY THERAPEUTICS CLASS, 2018-2030 (USD MILLION)
• TABLE 82. EUROPE, MIDDLE EAST & AFRICA OVARIAN CANCER DRUGS MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
• TABLE 83. EUROPE, MIDDLE EAST & AFRICA OVARIAN CANCER DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 84. EUROPE, MIDDLE EAST & AFRICA OVARIAN CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 85. DENMARK OVARIAN CANCER DRUGS MARKET SIZE, BY THERAPEUTICS CLASS, 2018-2030 (USD MILLION)
• TABLE 86. DENMARK OVARIAN CANCER DRUGS MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
• TABLE 87. DENMARK OVARIAN CANCER DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 88. EGYPT OVARIAN CANCER DRUGS MARKET SIZE, BY THERAPEUTICS CLASS, 2018-2030 (USD MILLION)
• TABLE 89. EGYPT OVARIAN CANCER DRUGS MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
• TABLE 90. EGYPT OVARIAN CANCER DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 91. FINLAND OVARIAN CANCER DRUGS MARKET SIZE, BY THERAPEUTICS CLASS, 2018-2030 (USD MILLION)
• TABLE 92. FINLAND OVARIAN CANCER DRUGS MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
• TABLE 93. FINLAND OVARIAN CANCER DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 94. FRANCE OVARIAN CANCER DRUGS MARKET SIZE, BY THERAPEUTICS CLASS, 2018-2030 (USD MILLION)
• TABLE 95. FRANCE OVARIAN CANCER DRUGS MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
• TABLE 96. FRANCE OVARIAN CANCER DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 97. GERMANY OVARIAN CANCER DRUGS MARKET SIZE, BY THERAPEUTICS CLASS, 2018-2030 (USD MILLION)
• TABLE 98. GERMANY OVARIAN CANCER DRUGS MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
• TABLE 99. GERMANY OVARIAN CANCER DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 100. ISRAEL OVARIAN CANCER DRUGS MARKET SIZE, BY THERAPEUTICS CLASS, 2018-2030 (USD MILLION)
• TABLE 101. ISRAEL OVARIAN CANCER DRUGS MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
• TABLE 102. ISRAEL OVARIAN CANCER DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 103. ITALY OVARIAN CANCER DRUGS MARKET SIZE, BY THERAPEUTICS CLASS, 2018-2030 (USD MILLION)
• TABLE 104. ITALY OVARIAN CANCER DRUGS MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
• TABLE 105. ITALY OVARIAN CANCER DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 106. NETHERLANDS OVARIAN CANCER DRUGS MARKET SIZE, BY THERAPEUTICS CLASS, 2018-2030 (USD MILLION)
• TABLE 107. NETHERLANDS OVARIAN CANCER DRUGS MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
• TABLE 108. NETHERLANDS OVARIAN CANCER DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 109. NIGERIA OVARIAN CANCER DRUGS MARKET SIZE, BY THERAPEUTICS CLASS, 2018-2030 (USD MILLION)
• TABLE 110. NIGERIA OVARIAN CANCER DRUGS MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
• TABLE 111. NIGERIA OVARIAN CANCER DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 112. NORWAY OVARIAN CANCER DRUGS MARKET SIZE, BY THERAPEUTICS CLASS, 2018-2030 (USD MILLION)
• TABLE 113. NORWAY OVARIAN CANCER DRUGS MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
• TABLE 114. NORWAY OVARIAN CANCER DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 115. POLAND OVARIAN CANCER DRUGS MARKET SIZE, BY THERAPEUTICS CLASS, 2018-2030 (USD MILLION)
• TABLE 116. POLAND OVARIAN CANCER DRUGS MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
• TABLE 117. POLAND OVARIAN CANCER DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 118. QATAR OVARIAN CANCER DRUGS MARKET SIZE, BY THERAPEUTICS CLASS, 2018-2030 (USD MILLION)
• TABLE 119. QATAR OVARIAN CANCER DRUGS MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
• TABLE 120. QATAR OVARIAN CANCER DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 121. RUSSIA OVARIAN CANCER DRUGS MARKET SIZE, BY THERAPEUTICS CLASS, 2018-2030 (USD MILLION)
• TABLE 122. RUSSIA OVARIAN CANCER DRUGS MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
• TABLE 123. RUSSIA OVARIAN CANCER DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 124. SAUDI ARABIA OVARIAN CANCER DRUGS MARKET SIZE, BY THERAPEUTICS CLASS, 2018-2030 (USD MILLION)
• TABLE 125. SAUDI ARABIA OVARIAN CANCER DRUGS MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
• TABLE 126. SAUDI ARABIA OVARIAN CANCER DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 127. SOUTH AFRICA OVARIAN CANCER DRUGS MARKET SIZE, BY THERAPEUTICS CLASS, 2018-2030 (USD MILLION)
• TABLE 128. SOUTH AFRICA OVARIAN CANCER DRUGS MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
• TABLE 129. SOUTH AFRICA OVARIAN CANCER DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 130. SPAIN OVARIAN CANCER DRUGS MARKET SIZE, BY THERAPEUTICS CLASS, 2018-2030 (USD MILLION)
• TABLE 131. SPAIN OVARIAN CANCER DRUGS MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
• TABLE 132. SPAIN OVARIAN CANCER DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 133. SWEDEN OVARIAN CANCER DRUGS MARKET SIZE, BY THERAPEUTICS CLASS, 2018-2030 (USD MILLION)
• TABLE 134. SWEDEN OVARIAN CANCER DRUGS MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
• TABLE 135. SWEDEN OVARIAN CANCER DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 136. SWITZERLAND OVARIAN CANCER DRUGS MARKET SIZE, BY THERAPEUTICS CLASS, 2018-2030 (USD MILLION)
• TABLE 137. SWITZERLAND OVARIAN CANCER DRUGS MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
• TABLE 138. SWITZERLAND OVARIAN CANCER DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 139. TURKEY OVARIAN CANCER DRUGS MARKET SIZE, BY THERAPEUTICS CLASS, 2018-2030 (USD MILLION)
• TABLE 140. TURKEY OVARIAN CANCER DRUGS MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
• TABLE 141. TURKEY OVARIAN CANCER DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 142. UNITED ARAB EMIRATES OVARIAN CANCER DRUGS MARKET SIZE, BY THERAPEUTICS CLASS, 2018-2030 (USD MILLION)
• TABLE 143. UNITED ARAB EMIRATES OVARIAN CANCER DRUGS MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
• TABLE 144. UNITED ARAB EMIRATES OVARIAN CANCER DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 145. UNITED KINGDOM OVARIAN CANCER DRUGS MARKET SIZE, BY THERAPEUTICS CLASS, 2018-2030 (USD MILLION)
• TABLE 146. UNITED KINGDOM OVARIAN CANCER DRUGS MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
• TABLE 147. UNITED KINGDOM OVARIAN CANCER DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 148. OVARIAN CANCER DRUGS MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 149. OVARIAN CANCER DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

The Ovarian Cancer Drugs Market was valued at USD 3.95 billion in 2023, expected to reach USD 4.49 billion in 2024, and is projected to grow at a CAGR of 13.75%, to USD 9.73 billion by 2030.

The scope of the ovarian cancer drugs market encompasses the development, production, and distribution of pharmacological treatments specifically designed to target ovarian cancer. This includes chemotherapeutic agents, targeted therapies, and immunotherapies. The necessity of ovarian cancer drugs is underscored by the high mortality rates associated with ovarian cancer, largely due to the often late-stage diagnosis, making effective drug therapies vital for improving survival rates and patient outcomes. Applications primarily include usage by oncologists and healthcare facilities for treatment regimes, with end-use spanning hospitals, specialty cancer treatment centers, and clinics.

Market growth is significantly influenced by factors such as advancements in personalized medicine, increased R&D investments, and expanding global awareness of the disease. The rise of innovative therapies, including targeted and combination therapies, offers substantial growth potential, as does the increasing regulatory approval of novel drugs. The growing demand for minimally invasive treatment options and improved therapeutic outcomes also creates new opportunities for market expansion. Recommendations to capitalize on these opportunities include investing in precision oncology and enhancing patient access through strategic partnerships.

However, the market faces limitations such as high drug development costs, stringent regulatory requirements, and potential side effects associated with existing therapies. Additionally, the genetic diversity of ovarian cancer makes it challenging to develop a one-size-fits-all treatment, often requiring complex treatment strategies.

Areas ripe for innovation include the development of biomarkers for early detection, novel drug delivery systems, and patient-specific treatment options leveraging artificial intelligence and genomic insights. Furthermore, the nature of the market is competitive yet collaborative, involving partnerships between pharmaceutical firms, biotechnology companies, and research institutions. Companies that focus on breakthrough therapies and adaptive clinical trial designs are well-positioned to lead in this evolving market landscape. Given these dynamics, stakeholders should prioritize patient-centric design and digitally integrated healthcare solutions to foster long-term innovation and growth.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Ovarian Cancer Drugs Market

The Ovarian Cancer Drugs Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Rising incidences of ovarian cancer around the globe
  • Increasing geriatric population of women around the world
  • Adoption of novel drugs and strong developmental pipeline
• Market Restraints
  • Adverse impact of cancer drugs on the human body
• Market Opportunities
  • Rising funding in the healthcare industry by the government in developing countries
  • Developments in ovarian cancer drugs in emerging economies
• Market Challenges
  • Cost associated with the treatment of ovarian cancer is high

Porter's Five Forces: A Strategic Tool for Navigating the Ovarian Cancer Drugs Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Ovarian Cancer Drugs Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Ovarian Cancer Drugs Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Ovarian Cancer Drugs Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Ovarian Cancer Drugs Market

A detailed market share analysis in the Ovarian Cancer Drugs Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Ovarian Cancer Drugs Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Ovarian Cancer Drugs Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Ovarian Cancer Drugs Market

A strategic analysis of the Ovarian Cancer Drugs Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Ovarian Cancer Drugs Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Alkem Laboratories Ltd., Allergan PLC, AstraZeneca PLC, Boehringer Ingelheim, Cipla Ltd., Clovis Oncology, F. Hoffmann-La Roche AG, Fresenius Kabi India Pvt. Ltd., GlaxoSmithKline PLC, Merck & Co., Inc., Mylan Pharmaceuticals Pvt. Ltd., Pfizer, Inc., Sanofi S.A., and Syndax Pharmaceuticals, Inc..

Market Segmentation & Coverage

This research report categorizes the Ovarian Cancer Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Therapeutics Class, market is studied across Angiogenesis Inhibitors, PARP Inhibitors, and PD-L1 Inhibitors.
• Based on Modality, market is studied across Chemotherapy, Hormonal Therapy, and Targeted Therapy.
• Based on Drugs, market is studied across Avastin, Carboplatin, Doxil, Lynparza, and Yondelis.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Rising incidences of ovarian cancer around the globe
    • 5.1.1.2. Increasing geriatric population of women around the world
    • 5.1.1.3. Adoption of novel drugs and strong developmental pipeline
  • 5.1.2. Restraints
    • 5.1.2.1. Adverse impact of cancer drugs on the human body
  • 5.1.3. Opportunities
    • 5.1.3.1. Rising funding in the healthcare industry by the government in developing countries
    • 5.1.3.2. Developments in ovarian cancer drugs in emerging economies
  • 5.1.4. Challenges
    • 5.1.4.1. Cost associated with the treatment of ovarian cancer is high
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Ovarian Cancer Drugs Market, by Therapeutics Class

• 6.1. Introduction
• 6.2. Angiogenesis Inhibitors
• 6.3. PARP Inhibitors
• 6.4. PD-L1 Inhibitors

7. Ovarian Cancer Drugs Market, by Modality

• 7.1. Introduction
• 7.2. Chemotherapy
• 7.3. Hormonal Therapy
• 7.4. Targeted Therapy

8. Ovarian Cancer Drugs Market, by Drugs

• 8.1. Introduction
• 8.2. Avastin
• 8.3. Carboplatin
• 8.4. Doxil
• 8.5. Lynparza
• 8.6. Yondelis

9. Americas Ovarian Cancer Drugs Market

• 9.1. Introduction
• 9.2. Argentina
• 9.3. Brazil
• 9.4. Canada
• 9.5. Mexico
• 9.6. United States

10. Asia-Pacific Ovarian Cancer Drugs Market

• 10.1. Introduction
• 10.2. Australia
• 10.3. China
• 10.4. India
• 10.5. Indonesia
• 10.6. Japan
• 10.7. Malaysia
• 10.8. Philippines
• 10.9. Singapore
• 10.10. South Korea
• 10.11. Taiwan
• 10.12. Thailand
• 10.13. Vietnam

11. Europe, Middle East & Africa Ovarian Cancer Drugs Market

• 11.1. Introduction
• 11.2. Denmark
• 11.3. Egypt
• 11.4. Finland
• 11.5. France
• 11.6. Germany
• 11.7. Israel
• 11.8. Italy
• 11.9. Netherlands
• 11.10. Nigeria
• 11.11. Norway
• 11.12. Poland
• 11.13. Qatar
• 11.14. Russia
• 11.15. Saudi Arabia
• 11.16. South Africa
• 11.17. Spain
• 11.18. Sweden
• 11.19. Switzerland
• 11.20. Turkey
• 11.21. United Arab Emirates
• 11.22. United Kingdom

12. Competitive Landscape

• 12.1. Market Share Analysis, 2023
• 12.2. FPNV Positioning Matrix, 2023
• 12.3. Competitive Scenario Analysis
• 12.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Abbott Laboratories
• 2. Alkem Laboratories Ltd.
• 3. Allergan PLC
• 4. AstraZeneca PLC
• 5. Boehringer Ingelheim
• 6. Cipla Ltd.
• 7. Clovis Oncology
• 8. F. Hoffmann-La Roche AG
• 9. Fresenius Kabi India Pvt. Ltd.
• 10. GlaxoSmithKline PLC
• 11. Merck & Co., Inc.
• 12. Mylan Pharmaceuticals Pvt. Ltd.
• 13. Pfizer, Inc.
• 14. Sanofi S.A.
• 15. Syndax Pharmaceuticals, Inc.